Elyxyb Patent Expiration

Elyxyb is a drug owned by Scilex Holding Co. It is protected by 6 US drug patents filed from 2020 to 2021 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be May 27, 2036. Details of Elyxyb's patents and their expiration are given in the table below.


Drug Patent Number Drug Patent Title Drug Patent Expiry Status
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10722456 Oral composition of celecoxib for treatment of pain
May, 2036

(11 years from now)

Active
US10799517 Oral composition of celecoxib for treatment of pain
May, 2036

(11 years from now)

Active
US9949990 Oral composition of celecoxib for treatment of pain
May, 2036

(11 years from now)

Active
US9795620 Oral composition of celecoxib for treatment of pain
May, 2036

(11 years from now)

Active
US9572819 Oral composition of celecoxib for treatment of pain
May, 2036

(11 years from now)

Active
US10376527 Oral composition of celecoxib for treatment of pain
May, 2036

(11 years from now)

Active


FDA has granted several exclusivities to Elyxyb. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Elyxyb, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Elyxyb.

Exclusivity Information

Elyxyb holds 1 exclusivities. All of its exclusivities have expired in 2023. Details of Elyxyb's exclusivity codes and their expiration dates are given below.


Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) May 05, 2023

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

US patents provide insights into the exclusivity only within the United States, but Elyxyb is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Elyxyb's family patents as well as insights into ongoing legal events on those patents.

Elyxyb's family patents

Elyxyb has patent protection in a total of 14 countries. It's US patent count contributes only to 32.4% of its total global patent coverage. 1 country has all of their patents expired or invalidated which has opened up potential generic launch opportunities in this particular country. Click below to unlock the full patent family tree for Elyxyb.

Family Patents

Coming Soon

Patent Strength Analyzer

Will this be useful for you?

YesNo

Thank you for your response 🥳



Generic Launch

Generic Release Date:

Elyxyb's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be May 27, 2036 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)

Elyxyb Generics:

Celecoxib is the generic name for the brand Elyxyb. 24 different companies have already filed for the generic of Elyxyb, with Yiling having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Elyxyb's generic





About Elyxyb

Elyxyb is a drug owned by Scilex Holding Co. It is used for treating acute migraine in adults. Elyxyb uses Celecoxib as an active ingredient. Elyxyb was launched by Scilex Hldg in 2020.

Market Authorisation Date:

Elyxyb was approved by FDA for market use on 05 May, 2020.

Active Ingredient:

Elyxyb uses Celecoxib as the active ingredient. Check out other Drugs and Companies using Celecoxib ingredient

Treatment:

Elyxyb is used for treating acute migraine in adults.

Dosage:

Elyxyb is available in solution form for oral use. Given below is detailed information on Dosage -

Strength Dosage Form Availability Application Pathway
25MG/ML SOLUTION Prescription ORAL